Windtree Therapeutics

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher Wednesday after the company announced topline results from the Phase 2 SEISMiC study of istaroxime in early cardiogenic shock. Istaroxime is a dual mechanism therapy designed to improve both systolic and diastolic cardiac.

Windtree Therapeutics Stock Is Trading Higher: Here's Why

Istaroxime significantly improved the systolic blood pressure profile Istaroxime significantly improved the systolic blood pressure profile

Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock

Company to present on Monday, April 4, 2022 at 11:00 am Company to present on Monday, April 4, 2022 at 11:00 am

Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference

WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided key business updates.

Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates

Windtree Therapeutics Inc (NASDAQ: WINT) announced results from its Phase 2 study of lucinactant (KL4 surfactant) for severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury. The Phase 2 trial was designed to assess reconstituted lyophilized lucinactant.

Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress

Results support the feasibility for development of a potential treatment for critically ill patients with ARDS due to COVID-19 and other causes Results support the feasibility for development of a potential treatment for critically ill patients with ARDS due to COVID-19 and other causes

Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury

On track for top-line data in April 2022 On track for top-line data in April 2022

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15 at 1:20 p.m. Eastern Time.

Windtree to Present at Oppenheimer's 32nd Annual Healthcare Conference

Windtree Therapeutics Inc WINT has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Data is anticipated in Q1 of 2022.

Why Are Windtree Therapeutics Shares Trading Higher Today?

Data anticipated in first quarter 2022 Data anticipated in first quarter 2022

Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome

New Patent Provides Intellectual Property Protection Through Late 2039 New Patent Provides Intellectual Property Protection Through Late 2039

Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent

This strategy identified LGVN stock a month ago, and now its price has skyrocketed. Here are two more biotechs that could do the same.

2 Moonshot Biotechs with 10x Potential

Windtree Is Studying Istaroxime in Early Cardiogenic Shock Patients Windtree Is Studying Istaroxime in Early Cardiogenic Shock Patients

Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation

WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2021 and provided key business updates.

Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates

Digital World Acquisition Corp

Volcon

Byrna Technologies

Insiders often know things the general public doesn't yet, which means that an otherwise unexciting company with insider trades can be great. The post 3 Moonshot Stocks Insiders Are Buying… and 2 That Are Getting Dumped appeared first on InvestorPlace.

3 Moonshot Stocks Insiders Are Buying… and 2 That Are Getting Dumped

Anticipated New Patent Will Provide Intellectual Property Protection Until Late 2039 Anticipated New Patent Will Provide Intellectual Property Protection Until Late 2039

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

Tuesday, October 19th @ 8:00 am Eastern Time Tuesday, October 19th @ 8:00 am Eastern Time

Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock

Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study

WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit.

Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

The stock price of Windtree Therapeutics Inc (NASDAQ: WINT) increased by over 50% pre-market. These are some details you should know.

WINT Stock Price Increases Over 50% Pre-Market: Details

WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates.

Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present at the Access to Giving Virtual Investor conference, which is being held virtually July 13–15, 2021.

Windtree to Present at Access to Giving Virtual Investor Conference

WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:

Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)

WARRINGTON, Pa., July 1, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Diane Carman, Esq.

Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel

The stock price of Windtree Therapeutics Inc (NASDAQ: WINT) increased by 36.36% on Friday, June 4. This is why it happened.

News for Windtree Therapeutics Stock (WINT)